These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30243312)

  • 1. Evocalcet in the management of secondary hyperparathyroidism in dialysis patients.
    Parfrey PS
    Kidney Int; 2018 Oct; 94(4):661-662. PubMed ID: 30243312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Fukagawa M; Shimazaki R; Akizawa T;
    Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.
    Akizawa T; Shimazaki R; Fukagawa M;
    PLoS One; 2018; 13(10):e0204896. PubMed ID: 30379826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism.
    Akizawa T; Ikejiri K; Kondo Y; Endo Y; Fukagawa M
    Ther Apher Dial; 2020 Jun; 24(3):248-257. PubMed ID: 31486206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA
    Tokunaga S; Endo Y; Kawata T
    Nihon Yakurigaku Zasshi; 2019; 154(1):35-43. PubMed ID: 31308348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis.
    Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C
    Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
    Ballinger AE; Palmer SC; Nistor I; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2014; 2014(12):CD006254. PubMed ID: 25490118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
    Kawata T; Tokunaga S; Murai M; Masuda N; Haruyama W; Shoukei Y; Hisada Y; Yanagida T; Miyazaki H; Wada M; Akizawa T; Fukagawa M
    PLoS One; 2018; 13(4):e0195316. PubMed ID: 29614098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
    Friedl C; Zitt E
    Drug Des Devel Ther; 2018; 12():1589-1598. PubMed ID: 29910605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
    Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
    Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
    Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K
    Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcimimetics versus parathyroidectomy: What is preferable?
    Rroji M; Spasovski G
    Int Urol Nephrol; 2018 Jul; 50(7):1271-1275. PubMed ID: 29532306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.
    Esteve Simo V; Moreno-Guzmán F; Martínez Calvo G; Fulquet Nicolas M; Pou Potau M; Macias-Toro J; Duarte-Gallego V; Saurina Sole A; Ramírez-de Arellano Serna M
    Nefrologia; 2015; 35(4):403-9. PubMed ID: 26306967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.
    Akizawa T; Shimazaki R; Shiramoto M; Fukagawa M;
    Clin Drug Investig; 2018 Oct; 38(10):945-954. PubMed ID: 30168004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients.
    Bashir SO; Omer HA; Aamer MA; Somialy R; Morsy MD
    Saudi J Kidney Dis Transpl; 2015 Nov; 26(6):1135-41. PubMed ID: 26586050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.
    Srinivas NR
    Clin Drug Investig; 2019 Jan; 39(1):105-107. PubMed ID: 30632108
    [No Abstract]   [Full Text] [Related]  

  • 18. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to Comments on "Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study".
    Akizawa T; Shimazaki R; Shiramoto M; Fukagawa M;
    Clin Drug Investig; 2019 Jan; 39(1):109-111. PubMed ID: 30632107
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacodynamics of cinacalcet over 48 hours in patients with controlled secondary hyperparathyroidism: useful data in clinical practice.
    Arenas MD; de la Fuente V; Delgado P; Gil MT; Gutiérrez P; Ribero J; Rodríguez M; Almadén Y
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1718-25. PubMed ID: 23463658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.